Hisamitsu Pharmaceutical Co (TSE:4530) Total Liabilities : 円63,417 Mil (As of Nov. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Total Liabilities?

Hisamitsu Pharmaceutical Co's Total Liabilities for the quarter that ended in Nov. 2023 was 円63,417 Mil.

Hisamitsu Pharmaceutical Co's quarterly Total Liabilities increased from May. 2023 (円58,558.00 Mil) to Aug. 2023 (円69,197.00 Mil) but then declined from Aug. 2023 (円69,197.00 Mil) to Nov. 2023 (円63,417.00 Mil).

Hisamitsu Pharmaceutical Co's annual Total Liabilities increased from Feb. 2022 (円47,976.00 Mil) to Feb. 2023 (円55,513.00 Mil) and increased from Feb. 2023 (円55,513.00 Mil) to Feb. 2024 (円61,703.00 Mil).

Hisamitsu Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Total Liabilities Chart

Hisamitsu Pharmaceutical Co Annual Data

Trend

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Total Liabilities

Get a 7-Day Free Trial

56,660.00

46,056.00

47,976.00

55,513.00

61,703.00

Hisamitsu Pharmaceutical Co Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Liabilities	Get a 7-Day Free Trial															55,513.00	58,558.00	69,197.00	63,417.00	61,703.00

Hisamitsu Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hisamitsu Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Feb. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	45938	+	(679	+	6488
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	8598)
	=	61,703

Total Liabilities	=	Total Assets (A: Feb. 2024 )	-	Total Equity (A: Feb. 2024 )
	=	328779	-	267076
	=	61,703

Hisamitsu Pharmaceutical Co's Total Liabilities for the quarter that ended in Nov. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	50346	+	(95	+	4389
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	8587)
	=	63,417

Total Liabilities	=	Total Assets (Q: Nov. 2023 )	-	Total Equity (Q: Nov. 2023 )
	=	334909	-	271492
	=	63,417

Hisamitsu Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HPX:Germany

Address

408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017

Website

http://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines